Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Overview: Gilead is a biopharmaceutical company focused on antivirals, antifungals, and antibacterials for life-threatening infectious diseases. The company markets six products globally, with a primary focus on HIV (Viread), Hepatitis B (Hepsera), and fungal infections (AmBisome). In January 2003, shortly after the reporting period, Gilead completed the acquisition of Triangle Pharmaceuticals, Inc. for approximately $525 million to expand its HIV and Hepatitis B pipeline.
Key Financial Metrics
| Metric | 2002 | 2001 | 2000 |
|---|---|---|---|
| Total Revenues | $466.8 million | $233.8 million | $195.6 million |
| Net Product Sales | $423.9 million | $191.0 million | $149.7 million |
| Income from Operations | $81.0 million | ($120.7 million) | ($52.3 million) |
| Net Income | $72.1 million | $52.3 million | ($56.8 million) |
| Diluted EPS | $0.35 | $0.26 | ($0.31) |
| Product Gross Margin | 83.6% | 77.1% | 77.6% |
| Cash & Equivalents | $942.4 million | $582.9 million | $512.9 million |
| Working Capital | $1,078.9 million | $627.6 million | $535.6 million |
| Convertible Debt | $595.0 million | $250.0 million | $250.0 million |
Note: 2001 Net Income included a one-time non-operating gain of $157.8 million from the sale of oncology assets. 2002 Net Income included a $16.0 million loss on the sale of marketable securities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 100% to $466.8 million, driven primarily by a 1,350% increase in Viread sales ($225.8 million in 2002 vs. $15.6 million in 2001). AmBisome sales grew 13% to $185.7 million.
- Profitability: The company achieved its first full year of operating profitability ($81.0 million) compared to an operating loss of $120.7 million in 2001. This shift was due to revenue growth and a $50.8 million reduction in R&D expenses (excluding oncology divestiture impacts).
- Debt Issuance: In December 2002, Gilead issued $345.0 million of 2% convertible senior notes due 2007, increasing total convertible debt to $595.0 million.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 45% to $181.3 million due to expanded sales forces for Viread and Hepsera.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Viread: Management expects 2003 sales to approximately double, ranging from $425 million to $475 million.
- AmBisome: Due to increasing competition, 2003 sales are expected to decline to a range of $160 million to $170 million.
- Hepsera: Sales began in September 2002 ($4.2 million). Management expects this product to become a substantial revenue source in the foreseeable future.
- Expenses: Excluding the Triangle acquisition, R&D expenses are projected to be $160–$180 million in 2003, and SG&A expenses are projected to be $250–$270 million.
Risks and Contingencies
- Triangle Acquisition Integration: Risks include the failure to integrate Triangle's operations, delays in regulatory approval for emtricitabine, and the inability to manufacture emtricitabine at a reasonable cost due to reliance on third-party manufacturer Abbott (which has recent FDA compliance issues).
- Product Liability and Safety: Post-approval safety issues, such as kidney toxicity reported with Viread, could limit market acceptance or require label changes.
- Competition: The HIV market is crowded with 20 branded drugs. AmBisome faces strong competition from new antifungal agents (e.g., Caspofungin, Voriconazole).
- International Credit Risk: Significant accounts receivable balances in Greece, Spain, Portugal, and Italy are subject to payment delays due to government reimbursement practices. Approximately $26.6 million of these receivables were more than 120 days past due as of year-end.
- Legal Proceedings: An ongoing dispute with University License Equity Holdings, Inc. (ULEHI) regarding the SELEX technology licensing agreement could result in arbitration and potential loss of rights.
Investor Verification Checklist
- Triangle Acquisition Impact: Verify the final accounting treatment of the $525 million Triangle acquisition and the timeline for emtricitabine regulatory approval (FDA review date set for July 3, 2003).
- Abbott Manufacturing Status: Confirm the resolution of FDA Form 483 observations at Abbott Laboratories, the designated manufacturer for emtricitabine, to assess launch risks.
- European Receivables: Monitor the collection status of the $49.7 million in past-due receivables from European government-supported customers.
- Viread Market Penetration: Track the success of marketing efforts to expand Viread usage in treatment-naive patients, as current approval is primarily for treatment-experienced patients.
- AmBisome Competitive Landscape: Assess the market share erosion of AmBisome due to the launch of competing antifungal therapies.